Skin developer to start ulcer trial:
This article was originally published in Clinica
Executive Summary
Artificial skin developer Ortec International will begin early trials of its Composite Culture Skin (CCS) in September for treating venous ulcers. Subject to internal review board approval, the pilot trial will study up to 40 patients and follow them for six months after wound closure. New York-based Ortec then plans to begin a major FDA-approved trial in the first quarter of 2000. CCS is made from bovine collagen which is seeded with dermal and epidermal skin cells.